Coverage

Federation of BiH: pembrolizumab and atezolizumab now explicitly for lung cancer

With its decision of 23 September 2026 (Official Gazette of the Federation 76/26), the government changed the entries for pembrolizumab and atezolizumab on the Solidarity Fund list. We checked what this means for lung cancer.

  • Published on
  • Bosnia and Herzegovina
  • Checked against the source by the hub team on 19 November 2026

Most important in brief

  • Pembrolizumab: as a first treatment alone or with chemotherapy, and around surgery, before it together with chemotherapy and after it alone.
  • Atezolizumab: as a first treatment alone or in combination, after complete surgery with PD-L1 of 50% or more, and for extensive-stage small cell lung cancer with carboplatin and etoposide.

What applies now

Federation of Bosnia and Herzegovina

Solidarity Fund list (version 47/19, last amended by 76/26) · List (PDF), September 2026 update · checked on 19 November 2026

Hospital cancer medicines are paid by the Solidarity Fund, not the regular medicines list. The list includes standard chemotherapy, erlotinib, crizotinib, alectinib, nivolumab, pembrolizumab, atezolizumab and dabrafenib with trametinib (explicitly as first treatment for advanced NSCLC). Since September 2026 the list names lung cancer explicitly for pembrolizumab and atezolizumab: both as a first treatment alone or with chemotherapy and after complete surgery, pembrolizumab also before surgery, and atezolizumab also for extensive-stage small cell lung cancer.

Not on the list

Osimertinib, lorlatinib, brigatinib, durvalumab, and no medicine against KRAS G12C, RET, MET, NTRK or HER2.

What this means for you

If you are treated in the Federation, pembrolizumab and atezolizumab are now explicitly on the list for lung cancer: as a first treatment for advanced disease, usually without an EGFR or ALK change, and around surgery.

For extensive-stage small cell lung cancer this also applies to atezolizumab with chemotherapy.

This decision does not change anything in Republika Srpska. There, ask your care team what is paid.

More under Costs

Sources

  1. Službene novine FBiH 76/26, 25.09.2026
  2. Federalno ministarstvo zdravstva: liste lijekova

Source checked on 19 November 2026

All updates